India’s equity market may be under pressure, but the broader setup is not broken enough to rule out stock-specific gains in a weak tape, with analysts pointing to pharma, healthcare and select banking names as pockets where earnings resilience can still attract buyers.
India Nifty Slips; Laurus Labs, Bandhan Bank Setups
That matters because the current slide in the Nifty and Bank Nifty is squeezing the index-level trade, but not every company is weakening at the same pace. For investors, the distinction is critical: when market structure turns “sell on rise,” capital tends to rotate away from broad beta and toward stocks with cleaner earnings visibility, stronger charts and defensible support levels.
Axis Securities’ Rajesh Palviya said the Nifty has slipped below key moving averages and is now trading near 23,650, with the market structure deteriorating after a break of 23,800. He said rallies are likely to face selling pressure unless the index can sustain above 23,850-23,900 on a closing basis. If 23,650 gives way, he sees room for a decline toward 23,500. Bank Nifty, meanwhile, has slipped below 57,000, with 57,500 acting as a level that needs to be reclaimed to ease near-term weakness.
That index damage helps explain why stock selection is taking precedence over directional index bets. In a market where the 50-day moving average is being lost and momentum is fading, traders typically want names that are either consolidating before an upside breakout or showing early reversal signals after a correction.
Among the preferred ideas, Laurus Labs stands out as the clearest earnings-and-chart combination. Palviya said the pharma stock has resumed strength after a consolidation phase and could move back toward its all-time high. He recommended buying the stock for a target of 1,940-1,950 rupees, with a stop loss around 1,845. The pitch reflects a broader theme in the market: pharma and healthcare are acting as relative defensives even as index-level sentiment deteriorates.
Bandhan Bank is the other name drawing attention, with Palviya saying the stock is showing initial signs of a trend reversal on the daily chart after a correction. He sees upside toward 180 rupees if it can sustain above 167, a level that also offers a nearby reference point for risk control. For banks, the implication is that the sector is not uniformly weak even as Bank Nifty struggles below resistance; selective private lenders can still attract flows if they stabilize faster than the index.
The key investor takeaway is that this is still a market for selective accumulation, not aggressive index buying. Momentum appears to be surviving in a narrow set of pharma, healthcare, metal, auto and new-age names, but broad participation remains limited and profit-taking dominates elsewhere. Until Nifty reclaims 23,850-23,900 and Bank Nifty gets back above 57,500, rallies are likely to be sold into — leaving traders to focus on individual earnings stories rather than market-wide conviction.
| Entity | Gains | Losses |
|---|---|---|
| Laurus Labs | ▲Relative momentum buyers | ▼Index-level sellers |
| Bandhan Bank | ▲Selective dip buyers | ▼Weak-bank basket |
| Pharma/healthcare stocks | ▲Defensive flows | ▼Broad market beta |
| Nifty/Bank Nifty longs | ▲Reclaim of key resistances | ▼Sell-on-rise traders |



